- Rockland, MA US
Dr. Norma Muurahainen is a senior medical director at EMD Serono Research Institute (Rockland, Massachusetts), a business affiliated with Merck KGaA (Darmstadt Germany). Dr Norma Muurahainen received her MD from the University of Rochester School of Medicine (Rochester NY) and her PhD in human nutritional biochemistry is from Columbia University (NY,NY).
During the course of her career, Dr. Norma Muurahainen has practiced medicine, conducted clinical research, and received numerous recognitions as a medical professional. She joined EMD Serono in 1997, where her responsibilities include overseeing the acquisition, development, and clinical trials of new drugs. She has been involved in projects and publications in HIV medicine, endocrinology and osteoarthritis. Recently, Dr Norma Muurahainen was invited to speak at the 2016 OARSI World Congress on Osteoarthritis in Amsterdam.
Dahlberg LE, Aydemir A, Muurahainen N, Gühring H, Fredberg Edebo H, Krarup-Jensen N, Ladel CH, Jurvelin JS. A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. Clin Exp Rheumatol. 2016 March 23. [Epub]
Kwoh C, Muurahainen N, Aydemir A, Ashbeck E, Hannon M, Eckstein F, Hochberg M. Two-year changes in cartilage thickness on quantitative magnetic imaging (qMRI) and joint space width (JSW) on X-ray demonstrate similar predictive performance for knee replacement in OA subjects eligible for clinical trials. Osteoarthritis and Cartilage, 2016 [in press]
Marhardt K, Muurahainen N. Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin. Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S13.[EPub]
Roemer F, Aydemir A, Lohmander S, Crema M, Marra MD, Muurahainen N, Eckstein F, Guermazi A. Structural Effects of Sprifermin in Knee Osteoarthritis: A Post-Hoc Analysis on Cartilage and Non-Cartilaginous Tissue Alterations [Abstract] Arthritis Rheumatol. 2015; 67 (suppl. 10) [ACR EPub]